O
Oligomerix
Develops target identification and validation technologies enhancing the drug discovery process for neurodegenerative diseases
About Oligomerix
Oligomerix is a biotechnology company focused on developing innovative small molecule drugs that target tau oligomers, which are linked to neurotoxicity and disease progression in neurodegenerative diseases. The company operates in the pharmaceutical and biotechnology market, primarily serving patients suffering from conditions such as Alzheimer's disease and other related neurodegenerative disorders. Oligomerix's business model revolves around research and development, with a strong emphasis on discovering novel and differentiated small molecules and biomarkers that inhibit tau oligomers. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. With a leadership team comprising experienced professionals from the pharmaceutical industry, Oligomerix is well-positioned to advance its mission of providing disease-modifying treatments for neurodegenerative diseases.
Source: Dealroom company dataAt a glance
- Founded
- 2006
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Alzheimer's Drug Discovery Foundation
Small Business Innovation Research
National Institutes of Health
National Institute on Aging
Series A1 investor entered at this stage
- WPWheatley Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oligomerix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oligomerix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.